Skip to main content


Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits

Fig. 6

Combination of vemurafenib and melatonin inhibited tumor growth and CSCs properties in mice. (a). The morphology of tumor xenografts of each nude mice after anatomy at 15 days of treatment. (b). Tumor volume of each group of nude mice was measured and calculated as V = (width2 × length)/2. (c). Tumor weight of each group of nude mice was measured, *P < 0.05. (D). Limiting dilution assays was performed and the finally formed tumors were calculated. (e-f). The expression levels o of iNOS, hTERT, p65, CD44, Epcam, PCNA expression from tumor exnografts in each group of nude mice by western blot (e) and immunohistochemistry assay (f). The data in panels are presented as the mean ± SD of three tests. P < 0.05, significant differences between treatment groups and DMSO control groups n = 5 mice/group. Magnification, 100 ×

Back to article page